These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 19557469)
61. Atezolizumab in invasive and metastatic urothelial carcinoma. Crist M; Balar A Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1295-1301. PubMed ID: 28994323 [TBL] [Abstract][Full Text] [Related]
62. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Sonpavde G; Bellmunt J; Rosenberg JE; Regazzi AM; Bajorin DF; Choueiri TK; Qu AQ; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Fougeray R; Wong YN; Sridhar SS; Ko YJ; Milowsky MI; Galsky MD; Pond GR Clin Genitourin Cancer; 2014 Dec; 12(6):395-8. PubMed ID: 25035282 [No Abstract] [Full Text] [Related]
63. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer. Raggi D; Necchi A; Giannatempo P Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336 [TBL] [Abstract][Full Text] [Related]
64. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Raj GV; Karavadia S; Schlomer B; Arriaga Y; Lotan Y; Sagalowsky A; Frenkel E Cancer; 2011 Jan; 117(2):276-82. PubMed ID: 20830767 [TBL] [Abstract][Full Text] [Related]
65. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden. Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001 [TBL] [Abstract][Full Text] [Related]
66. Counter-point. Routine use of perioperative intravesical chemotherapy after TURBT: against. Jones JS Urology; 2010 Oct; 76(4):797-8. PubMed ID: 20932404 [No Abstract] [Full Text] [Related]
68. Phase II study of everolimus in metastatic urothelial cancer. Smith AB; Pruthi RS BJU Int; 2013 Aug; 112(4):427-8. PubMed ID: 23879903 [No Abstract] [Full Text] [Related]
69. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? Berg S; D'Andrea D; Vetterlein MW; Cole AP; Fletcher SA; Krimphove MJ; Marchese M; Lipsitz SR; Sonpavde G; Noldus J; Shariat SF; Kibel AS; Trinh QD; Mossanen M Cancer; 2019 May; 125(9):1449-1458. PubMed ID: 30620387 [TBL] [Abstract][Full Text] [Related]
70. Systemic chemotherapy for advanced bladder cancer: update and controversies. Garcia JA; Dreicer R J Clin Oncol; 2006 Dec; 24(35):5545-51. PubMed ID: 17158540 [TBL] [Abstract][Full Text] [Related]
71. Durvalumab for the treatment of urothelial carcinoma. Alsharedi M; Srivastava R; Elmsherghi N Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083 [TBL] [Abstract][Full Text] [Related]
72. Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance. Gerullis H; Ecke TH; Janusch B; Arndt C; Heidari M; Oniani J; Otto T Anticancer Drugs; 2011 Oct; 22(9):940-3. PubMed ID: 21642839 [TBL] [Abstract][Full Text] [Related]
73. Management of advanced bladder cancer in the era of targeted therapies. Soave A; Engel O; Von Amsberg G; Becker A; Dahlem R; Shariat SF; Fisch M; Rink M Minerva Urol Nefrol; 2015 Jun; 67(2):103-15. PubMed ID: 25604695 [TBL] [Abstract][Full Text] [Related]
74. [Is there an indication for adjuvant or neoadjuvant systemic chemotherapy in bladder cancer?]. Suttmann H; Retz M; Gschwend JE; Stöckle M Urologe A; 2007 Oct; 46(10):1379-80, 1382-4. PubMed ID: 17805506 [TBL] [Abstract][Full Text] [Related]
75. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Benson MC Ann Oncol; 1999 Nov; 10(11):1269-70. PubMed ID: 10631452 [No Abstract] [Full Text] [Related]
76. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review. Pectasides D; Pectasides M; Nikolaou M Eur Urol; 2005 Jul; 48(1):60-7; discussion 67-8. PubMed ID: 15967253 [TBL] [Abstract][Full Text] [Related]
77. The role of adjuvant chemotherapy in locally advanced bladder cancer. Haque W; Lewis GD; Verma V; Darcourt JG; Butler EB; Teh BS Acta Oncol; 2018 Apr; 57(4):509-515. PubMed ID: 29226744 [TBL] [Abstract][Full Text] [Related]
78. Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012. Dinan MA; Georgieva MV; Li Y; Zhang T; Harrison M; Shenolikar R; Scales CD J Geriatr Oncol; 2021 Mar; 12(2):298-304. PubMed ID: 32912737 [TBL] [Abstract][Full Text] [Related]
79. Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients. Salzberg M; Borner M; Bauer JA; Morant R; Rauch D; Rochlitz C Eur J Cancer; 2006 Oct; 42(15):2660-1. PubMed ID: 16934972 [No Abstract] [Full Text] [Related]